Study of a BALB/c Mouse Model for Allergic Asthma

Young-Su Yang¹, Mi-Jin Yang¹, Kyu-Hyuk Cho¹, Kyuhong Lee¹, Yong-Bum Kim²,
Jin-Sung Kim², Myung-Gyu Kang³ and Chang-Woo Song¹

¹Division of Inhalation Toxicology, Jeonjeup Campus,
²Division of Toxicological Pathology,
³Division of Toxicology, Korea Institute of Toxicology, Daejeon 305-343, Korea

(Received August 13, 2008; Revised November 7, 2008; Accepted November 7, 2008)

INTRODUCTION

Allergic asthma is a worldwide public health problem and a major socioeconomic burden disease. It is a chronic inflammatory disease marked by airway eosinophilia and goblet cell hyperplasia with mucus hypersecretion. Mouse models have proven as a valuable tool for studying human asthma. In the present report we describe a comparison of mouse asthma models. The experiments were designed as follows: Group I was injected with ovalbumin (OVA, i.p.) on day 1 and challenged with 1% OVA (aerosol exposure) on days 14-21. Group II was injected on day 1, 14 and aerosol-immunized on days 14-21. Group III was injected on day 1, 14 and immunized by 1% OVA aerosol on days 18-21. We assessed asthma induction by determining the total number of white blood cells (WBC) and eosinophils as well as by measuring cytokine levels in bronchoalveolar lavage fluid (BALF). In addition, we evaluated the histopathological changes of the lungs and determined the concentration of immunoglobulin E (IgE) in serum. Total WBC, eosinophils, Th2 cytokines (IL-4, IL-13) and IgE were significantly increased in group I relative to the other groups. Moreover, histopathological studies show that group I mice show an increase in the infiltration of inflammatory cell-in peri-bronchial and perivascular areas as well as an overall increase in the number of mucus-containing goblet cells relative to other groups. These data suggest that group I can be a useful model for the study of human asthma pathobiology and the evaluation of existing and novel therapeutic agents.

Key words: Asthma, Mouse, Eosinophil, Immunoglobulin E, Cytokine, Model

Correspondence to: Chang-Woo Song, Division of Inhalation Toxicology, Korea Institute of Toxicology, Korea Research Institute of Chemical Technology 1051, Shijjeong-dong, Jeonjeup, Jeollabuk-do, 560-185, Republic of Korea
E-mail: cwsong@kitox.re.kr
Table 1. Representation of protocols for asthma induction in mice

| Strain       | Age & Gender | Sensitization          | Exposure                                                                 | Author                  |
|--------------|--------------|------------------------|--------------------------------------------------------------------------|-------------------------|
| BALB/c       | 7 weeks, male| 100 µg OVA + 1.6 mg Alum (i.p.) | Day 1                                                                   | El-Hashim et al. (2002) |
| BALB/c, C57BL6, C3H/He, AU | 5 weeks, male | 10 µg OVA + Alum gel (i.p.) | Day 1 and 14                                                             | Kazuhiko Shingawara and Masami Koijma (2003) |
| BALB/c       | 6 weeks, female| 20 µg OVA + 1 mg alum, day 1 and 10 (i.p.) | OVA (10 mg/ml) day 17, 24 and 31 (Aero)                                  | Jang et al. (2005)     |
| BALB/c       | 25-31 g, male | 20 µg OVA + 1 mg alum, day 1 (i.p.) | 5% OVA from day 14 to 21 (Aero)                                           | Park et al. (2007)     |
| BALB/c       | 5-7 weeks, male| 20 µg OVA + 4 mg alum, day 1 (i.p.) | 1% OVA from day 18 to 21 (Aero)                                          | Fred Wong et al. (2007) |
| BALB/c       | 6-8 weeks, female| 20 µg OVA + 1 mg Alum (i.p.) | Day 1 and 14                                                             | Yuk et al. (2007)      |
| BALB/c       | 20-25 g, male | 100 µg OVA + 10%, 50 mg Alum (i.p.) | Day 1 and 6                                                              | Sofia et al. (2008)    |
| C57BL6/J     | 17-24 g, female| 25 µg OVA + 2 mg alum, three weekly (i.p.) | 3 days/week (Aero)                                                      | Eric et al. (2008)     |

OVA: ovalbumin, Alum: aluminum hydroxide, IP: intra-peritoneal, IN: intra-nasal using micropipette, Aero: Aerolized using ultrasonic nebulizer

Cats may develop a bronchial disease that is similar to human chronic asthma (Padrid, 1992), and both sheep (Abraham, 1995) and dogs (De Weck et al., 1997) are known to have a natural susceptibility to some allergens. Guinea-pig models of asthma can provide the essential hallmarks of asthma, including dual bronchoconstrictor responses (Itoh et al., 1996; Toward et al., 2004). However, asthma models in mice are potentially more useful due to the fact that: i) their immune system has been widely characterized, ii) genetically modified mice are available and iii) a wide range of species-specific reagents can be obtained (Hessel et al., 1995; Torres et al., 2005). There have been a number of studies using acute exposures of mice to allergen, as shown in Table 1 (El-Hashim et al., 2002; Jing et al., 2005; Eric et al., 2008).

In the present work, we examined which mouse models are effective for investigation of human asthma. Asthma mice groups were designed based on preliminary studies in our laboratory and other studies in Table 1. Various parameters, such as differential cell count in a BALF (bronchoalveolar lavage fluid), histological examination and cytokines levels were measured as an indicator of asthma. These parameters are useful for determining asthma induction (El-Hashim et al., 2002; Jing et al., 2005; Eric et al., 2008), and they play an important role in human asthma (Yoshida et al., 2005).

MATERIALS AND METHODS

Chemicals. Chemicals were purchased from the following sources: Ovalbumin (OVA) from Sigma Co.; aluminum hydroxide from Pierce biotechnology, Inc.; Interleukin-4 (IL-4), Interleukin-5 (IL-5), Interleukin-13 (IL-13) and Immunoglobulin-E (IgE) immunoassay kits from Biosource international, Inc.; other chemicals were of the highest commercial grade available.

Animals and treatment. Female BALB/c mice (6 weeks old, Oriental Co., Ltd. Kyounggi, Korea) were kept in a storage room under the following conditions during the experiments: constant temperature (23±3°C), relative humidity (50±10%), and illumination (12 h light/ dark cycles). All animals were fed with standard animal chow daily and had access to drinking water ad libitum. The mice were divided into the following four groups (control group, asthma induction group I, II and III), and each group consisted of ten animals. For sensitization, group I, II, and III were treated with 20 µl of ovalbumin with 1 mg of aluminum hydroxide in 500 µl of saline, whereas the control group received 500 µl of saline intraperitoneally on day 1. Group II and III were treated for the second sensitization on day 14. As shown in Fig. 1, group I and II were challenged once daily from day 14 to day 21 by exposure to an aerosol of 1% OVA in saline using an ultrasonic nebulizer (3 ml/min, Omron, Tokyo, Japan). Group III was challenged three times a day from day 18 to day 21 by exposure to an aerosol of 1% OVA in saline. Mice of the control group were challenged with nebulized saline. All the animal facilities in this study were accredited by the Association for Assessment and Accreditation of Laboratory Animal Care International (AAALAC).
Collection of BALF (bronchoalveolar lavage fluid) and blood. Using isoflurane, the sensitized mice and the control mice were anesthetized, respectively. Blood was collected from the caudal vena cava for serum IgE measurements. The trachea of anesthetized mice was cannulated. Next, both lungs of each mouse tagged with an even number was lavaged with 1 ml of PBS three times. The collected BALF was pooled, and centrifuged at 3000 rpm for 4 min. The pellet was re-suspended with 500 µl of PBS.

Histological examination. The lung tissue of each mouse tagged with an odd number was fixed in a 10% formaldehyde solution at room temperature for 2 days, and then was paraffin-embedded. The tissues were sectioned at a thickness of 4 µm for histology. The sections were de-paraffinized with xylene, and then stained with haematoxylin and eosin (H&E) and periodic acid-Schiff (PAS) stain. All sections of the stained tissue were analyzed by bright-field microscopy.

Measurement of BALF cytokines and differential cell counts. Cytokine levels in BALF supernatant were measured using ELISA kits (Biosource, USA) according to the manufacturer’s instruction. IgE from serum was calculated by same method. Total and differential cell counts were performed using an ADVIA120 Hematology system (Bayer, USA).

Statistical analysis. Statistical analyses were performed using Statistical Analysis Systems (SAS/STAT User’s Guide Version 8.2, NC, USA). For all parameters, Bartlett’s test was performed according to whether a significant interaction was present or not, Dunn’s Rank Sum and ANOVA tests were used to compare the control group with experimental groups. Only if the differences exist. Student’s t-test was performed to test differences between a pair of each group. All results were calculated as the mean ± standard error of the mean and differences were considered significant when p < 0.05 or p < 0.01.

RESULTS

We induced asthma in BALB/c mice using the protocol illustrated in Fig. 1, and assessed the severity of asthma induction by counting the total number of white blood cells, eosinophils and by measuring cytokine levels in BALF. Also, the histopathological changes in lung tissue were characterized and the levels of immunoglobulin E (IgE) in serum were estimated.

Total leukocytes and eosinophils in BALF. Mice immunized with OVAalum and then challenged with OVA aerosol showed significant increases in the total white blood cells in BALF (Fig. 2A). The percentage of eosinophils was 4.06 ± 1.51% in control mice, 46.54 ± 6.88% in group I mice, 38.20 ± 4.80% in group II mice,
34.38 ± 3.64% in group III mice, respectively. Correspondingly, the number of eosinophils showed a marked increase (Fig. 2B). The numbers of eosinophils in BALF in group I (418 ± 144), group II (150 ± 26) and group III (148 ± 26) were increased in comparison with the control group (12 ± 6). Interestingly, the levels of eosinophils in group I are nearly three times as high as in the other two experimental groups.

**Th2 cytokine levels in BALF and IgE levels in serum.** Th2 cytokines play important roles in asthma during airway remodeling and the development of AHR. To determine the levels of cytokines (IL-4, IL-5 and IL-13) in BALF after repeated antigen exposure, ELISA studies were performed. IL-4 levels in BALF were slightly, but non-significantly, elevated in asthma induction groups, with the largest increase seen in group I (Fig. 3A). Levels of IL-5 and IL-13 were significantly increased in the asthma induction groups, except for group III in IL-5 level (Fig. 3B and 3C). In particular, IL-13 level in group I was significantly high compared with the level in other asthma induction groups (p < 0.01).
The serum levels of total IgE in all groups were significantly increased when compared with control mice (Fig. 4). Moreover, IgE level in group I showed statistical significance compared to the level in other asthma induction groups ($p < 0.01$).

**Histopathologic response of lung tissues.** We next made a histological analysis of lung sections taken from the four groups of mice after OVA exposure by nebulization. The morphological features of lung sections, which were stained with of Haematoxylin and eosin (H&E), are shown in Fig. 5. Asthma induction mice (Group I, II and III) showed a marked increase in the infiltration of inflammatory cells in the perivascular, bronchus and bronchiole areas (Fig. 5B, 5C and 5D, arrow). Many of the epithelial cells seemed to be enlarged due to the accumulation within their cytoplasm of homogeneous-looking material that stained positively with periodic acid-Schiff (PAS). PAS staining of lung tissue demonstrated a marked increase in goblet cells containing mucus as well as cell proliferation in the bronchial epithelium of OVA-allergic mice groups (Fig. 6B, 6C and 6D, arrow), as compared to the control group (Fig. 6A). Importantly, among the OVA-allergic mice groups, the incidence and severity of the
Histopathologic changes in the lungs were highest in group I (Table 2).

**DISCUSSION**

Many kinds of animal models have been developed to study the pathobiology of asthma; however, mice models are more useful than the others because: i) their immune systems are largely characterized, ii) genetically modified animals are available and iii) a wide range of species-specific reagents can be obtained (Torres et al., 2005; Hessel et al., 1995). As shown in Table 1 there are many variations on asthma mouse models, each with different protocols for sensitization and exposure periods. In this study, we have selected the BALB/c strain, because it produces higher levels of anti-ovalbumin IgE antibody and Th2 cytokines than other strains (Rakesh et al., 2008). For sensitization, ovalbumin and aluminum hydroxide are most commonly used with various doses for intraperitoneal injection as shown in Table 1 (Fred Wong et al., 2007; Park

| Group | Female |
|-------|--------|
|       | Control | Group I | Group II | Group III |
| Lung  | 10      | 10      | 10       | 10        |

| Inflammatory cell infiltration | Minimal | Mild | Moderate | Marked |
|--------------------------------|---------|------|----------|--------|
| Minimal                        | 0       | 0    | 0        | 1      |
| Mild                           | 0       | 3    | 6        | 4      |
| Moderate                       | 0       | 6    | 4        | 5      |
| Marked                         | 0       | 1    | 0        | 0      |

| Mucus hyperplasia | Minimal | Mild | Moderate | Marked |
|-------------------|---------|------|----------|--------|
| Minimal           | 1       | 0    | 0        | 0      |
| Mild              | 0       | 0    | 2        | 4      |
| Moderate          | 0       | 6    | 8        | 6      |
| Marked            | 0       | 4    | 0        | 0      |
The aim of this study is to establish the most efficient mouse model for investigation of human asthma. Asthma mice groups were designed based on preliminary studies in our laboratory and other studies in Table 1. Therefore, we chose to sensitize with 20 µg ovalbumin + 1 mg aluminum hydroxide for 7 weeks old mice. There are some reports about the impact of the size and type of exposure chamber on the results of similar experiments; for example, Sofia et al. (2008) used a chamber measuring 14.5 cm × 28.5 cm × 15 cm, and Jiang et al. (2005) used a chamber measuring, 440 cm³ (diameter 12 × 12 cm, height 10 cm). Interestingly, a tetrahedron-shaped chamber was not good for asthma induction because mice were crowded in a corner of the chamber. Consequently, some mice could not be induced properly leading to large deviation of parameter's value. Therefore, in order to remove this problem, a cylindrical exposure chamber was used in this study (radius 12.5 cm, height 10 cm).

Based on the above information, three groups of allergic asthma BALB/c mice models were designed, group I and group II were planned to determine the sensitization effect while group III was intended to allow for examination of exposure time effect. The results of these studies indicate that all three of these asthma induction models (especially group I) were useful for evaluating asthma, as demonstrated by the following four main reasons:

1. Eosinophilic inflammation was observed in the asthma induction groups. Mice immunized with OVA/alum and then challenged with an OVA aerosol showed a significant increase in total while blood cell count in BALF when compared with the control group. Specifically, the numbers of eosinophils in BALF of group I, II and III were significantly higher than the control group. Eosinophils are implicated as key effector cells in asthmatic Airways since they secrete cytotoxic proteins and lipid mediators that have the capacity to promote pathological changes believed to contribute to the decline in lung function (Martin et al., 1996).

2. Th2 Cytokine levels in BALF were elevated in the asthma induction groups, relative to the control group. In humans, expression levels of IL-4, IL-5 and IL-13 were increased in the bronchial mucosa of human asthmatics (Kay, 1997; Humbert, 1997). Studies concerning asthma suggest the importance of Th2 cytokines secreted by resident cells, such as epithelial cells, macrophages and mast cells, as well as infiltrated cells (eosinophils and lymphocytes) (Yuk et al., 2007; Barnes et al., 1998). IL-4 and IL-13 play important roles in IgE switching in B cells, the development of eosinophil infiltration into the airways and mucus hypersecretion (Kips, 2001). IL-5 is an essential molecule for the terminal differentiation, migration, and prolonged survival of eosinophils and airway hyperresponsiveness (Cho et al., 2004; Kips, 2001).

3. IgE levels in serum were elevated in the asthma-induced groups, as shown Fig. 4. The asthmatic response after antigen inhalation in patients with allergic asthma results from an IgE-dependent type-I hypersensitivity reaction (Hamid et al., 2003). IgE is associated with the early phase of allergic asthma (Kim and Heo, 2001). After the binding of the allergen to IgE, the complex interacts with the IgE receptor and activates mast cells to secret numerous mediators, causing symptoms of the disease to worsen (Owen, 2007).

4. Marked histological changes were observed in the asthma models. In our histological investigation, inflammatory cells had infiltrated into the perivascular, bronchus and bronchiolé area. Moreover, PAS staining of lung tissue demonstrated a marked increase in the number of goblet cells containing mucus as well as an increase in cell proliferation in the bronchial epithelium of OVA-allergic mice groups, when compared with the control group.

As shown above, all asthma-induced models described in this study were successful in the expression of asthma symptoms, especially group I. It can not be clearly determined why this is the case, however, we speculate that it may be a result of antigen-tolerance. Swirls and coworkers recently reported the importance of the granulocyte-macrophage colony-stimulating factor in BALB/c mice which are chronically exposed to antigen (Swirls et al., 2002). They showed that in antigen-tolerant mice, eosinophilia was fully restored by repeated antigen exposure. Another study showed that no airway lesions were seen and that no AHR was elicited in C57BL/6 mice when they were exposed to low levels of aerosolized antigen (Kazuhiko Shinagawa and Masami Kojima, 2003; Temelkovski et al., 1998; Kumar and Foster, 2002). In addition, some hypotheses can be made based on this. (1) The Exposure period was more important than number of sensitization in regulating the number of eosinophils. As shown in Fig. 2(B) & Fig. 3(C), the number of eosinophils and the concentration of IL-13 in group I were higher than those of other asthma groups, while IL-13 values in group II and III were similar. (2) IL-5 and IgE levels are not affected by exposure periods or the number of sensitizations. Since all asthma-induced groups showed similar levels of both. However, a more detailed examination is needed to confirm these results and to better understand the mechanisms of asthma. It was clear that the protocol
used for antigen sensitization/challenge is very important to sustaining the allergic reaction.

In summary, to make a good asthma model, it appears as though one sensitization is better than more than one and longer challenge periods are better than extensive short periods. If sensitization is to be done twice or for long exposure times, you must increase the OVA concentration during the challenge phase. Asthma models of BALB/c were useful for evaluating asthma, especially group I. We make this claim based on the observed increase seen in: i) total WBC, ii) eosinophils, iii) Th2 cytokines in BALF and iv) IgE levels in serum in observed increase seen in: i) total WBC, ii) eosinophils, especially group I. We make this claim based on the extensive short periods. If sensitization is to be done than one and longer challenge periods are better than used for antigen sensitization/challenge is very important to sustaining the allergic reaction.

ACKNOWLEDGEMENTS

This study was supported by the Ministry of Science and Technology for the General Project grant of the establishment of the International Inhalation Toxicology Evaluation Technology of Korea Institute of Toxicology.

REFERENCES

Abraham, W.M. (1995). Animal models of late bronchial responses. Eur. Respir. Rev., 5, 211-217.

Armin, B., Thomas, T. and David, A.G. (2008). Editorial: Experimental models of asthma. J. Occu. Med. and Toxicol., 3, Suppl 1, S1.

Barnes, P.J., Chung, K.F. and Page, C.P. (1998). Inflammatory mediators of asthma: an update. Pharmacol. Rev., 50, 515-566.

Blanchard, C., Mishra, A., Saibo-Akei, H., Monk, P., Anderson, I. and Rothenberg, M.E. (2005). Inhibition of human interleukin-13-induced respiratory and esophageal inflammation by anti-human interleukin-13 antibody (CAT-364). Clin. Exp. Allergy, 35, 1095-1103.

Bousquet, J., Chanez, P., Lacoste, J.Y., Baronnet, G., Ggavanian, N., Enander, I., Venge, P., Ahlstedt, S., Simony-Lafontaine, J. and Goard, P. (1960). Eosinophilic inflammation in asthma. N. Engl. J. Med., 323, 1033-1039.

Bousquet, J., Jeffery, P.K., Busse, W.W., Johnson, M. and Vignola, A.M. (2000). Asthma from bronchoconstriction to airways remodeling and remodeling. Am. J. Respir. Crit. Care Med., 161, 1720-1745.

Cho, J.Y., Miller, M., Baek, K.J., Han, J.W., Nayar, J., Lee, S.Y., McElvain, K., McElvain, S., Friedman, S. and Broide, D.H. (2004). Inhibition of airway remodeling in IL-5 deficient mice. J. Clin. Invest., 113, 551-560.

De Weck, A.L., Mayer, P., Stumper, B., Schiessel, B. and Pickart, L. (1997). Dog allergy, a model for allergy genetics. Int. Arch. Allergy Immunol., 113, 65-67.

El-Hashim, A.Z., Wyss, D. and Zuamy-Amorim, C. (2002). Kinetics of airway hyperresponsiveness and airway eosinophilia in BALBc mice and their modulation by different dexamethasone treatment regimens. Pulmonary Pharmacol. & Ther., 15, 467-475.

Eric, R., Secor, J., William, F., Carson, I.V., Anurag, S., Mellisa, P., Linda, A., Guemsey, C.M., Schramm and Roger S.T. (2008) Oral ovalbumin attenuates inflammation in an ovalbumin-induced murine model of asthma. eCAM, 5, 61-69.

Flood-Page, P., Menzies-Gow, A., Phipps, S., Ying, S., Vangoo, A., Ludwig, M.S., Barnes, N., Robinson, D. and Kay, A.B. (2003). Anti-IL-5 treatment reduces deposition of ECM proteins in the bronchial subepithelial basement membrane of mild atopic asthmatics. J. Clin. Invest., 112, 1029-1036.

Fred Wonga, W.S., Hua, Z. and Wipeng, L. (2007). Cysteinyi leukotriene receptor antagonist MK-571 alters bronchoalveolar lavage fluid proteome in a mouse asthma model. Euro. J. Phar., 575, 134-141.

Fulkerson, P., Fischetti, C., Hassman, L., Nikolaidis, N.M. and Rothenberg, M.E. (2008). Persistent effects induced by IL-13 in the lung. Am. J. Respir. Cell. Mol. Biol., 35, 337-346.

Hamid, Q., Tulic, M.K., Liu, M.C. and Mocqbel, R. (2003). Inflammatory cells in asthma: mechanisms and implications for therapy. J. Allergy Clin. Immunol., 111, S5-S17.

Heo, Y. and Kim, K.H. (2002). Development of subacute animal model to predict occurrence of systemic anaphylaxis following vaccination and evaluation of various immunotoxicological parameters. J. Toxicol. Pub. Health, 18, 205-213.

Hessel, E.M., Van Oosterhout, A.J., Hofstra, C.L., De Bie, J.J., Garssen, J., Van Loveren, H., et al. (1999). Bronchoconstriction and airway hyperresponsiveness after ovalbumin inhalation in sensitized mice. Eur. J. Pharmacol., 293, 401-412.

Humbert, M., Durham, S.R., Kimmitt, P., Powell, N., Assoufi, B., Pfister, R., Menz, G., Kay, A.B. and Corrigan, C.J. (1997). Elevated expression of messenger ribonucleic acid encoding IL-13 in the bronchial mucosa of atopic and nonatopic subjects with asthma. J. Allergy Clin. Immunol., 99, 657-665.

Kim, H.A. and Heo, Y. (2001). Significance of a highly specific and sensitive enzyme linked immunosorbent assay on evaluation of environmental toxicant-mediated allergic responses. J. Toxicol. Pub. Health, 17, 197-199.

Itoh, K., Takehashi, E., Mukaiyama, O., Sato, Y. and Yamaguchi, T. (1996). Relationship between airway eosinophilia and airway hyperresponsiveness in a late asthmatic model of guinea pigs. Int. Arch. Allergy Immunol., 109, 65-94.

Jiang, J.H., Li, G.Z., Chai, O.H. and Song, C.H. (2005). Increased intraepithelial mast cells in pulmonary airways of mouse asthma model. The Korean J. Anat., 38, 173-179.

Johnson, P.R.A., Roth, M., Tamm, M., Hughes, M., Ge, Q., King, G., Burgess, J.K. and Black, J.L. (2001). Airway smooth muscle cell proliferation is increased in asthma. Am. J. Respir. Crit. Care Med., 164, 474-477.

Karol, M.H. (1994). Animal models of occupational asthma. Eur. Respir. J., 7, 555-568.
Kasaian, M.T., Donaldson, D.D., Tchistiakova, L., Marquette, K., Tan, X.Y., Ahmed, A., Jacobson, B.A., Widom, A., Cook, T.A., Xu, X., Barry, A.B., Goldman, S.J. and Abraham, W.M. (2007). Efficacy of IL-13 neutralization in a sheep model of experimental asthma. *Am. J. Respir. Cell. Mol. Biol.* **36**, 368-376.

Kay, A.B., Barata, L., Meng, Q., Durham, S.R. and Ying, S. (1997). Eosinophils and eosinophil-associated cytokines in allergic inflammation. *Int. Arch. Allergy Immunol.*, **113**, 196-199.

Kazuhiko, S and Masami, K. (2003). Mouse Model of Airway Remodeling. *Ame. J. Res. Critical Care Med.*, **168**, 989-997.

Kips, J.C. (2001). Cytokines in asthma. *Eur. Respir. J. Suppl.*, **34**, 24-33.

Kumar, R.K. and Foster, P.S. (2002). Modeling allergic asthma in mice: pitfalls and opportunities. *Am. J. Respir. Cell. Mol. Biol.*, **27**, 267-272.

Martin, L.B., Kita, H., Leiferman, K.M. and Gleich, G.J. (1999). Eosinophils in allergy: role in disease, degranulation and cytokines. *Int. Arch. Allergy Immunol.*, **109**, 207-215.

McDonald, D.M. (2001). Angiogenesis and remodeling of airway vasculature in chronic inflammation. *Am. J. Respir. Crit. Care Med.*, **164**, 39-45.

Meryn, H., Karol, J.M., Matheson, R.W., Large, R.L. and Michael, I.L. (2001). Use of tumor necrosis factor receptor (TNFR)-knockout mice to probe the mechanism of chemically-induced asthma. *J. Toxicol. Pub. Health.*, **17**, 305-307.

Owen, C.E. (2007). Immunoglobulin E: role in asthma and allergic disease: lessons from the clinic. *Pharmacol. Ther.*, **113**, 121-133.

Padrid, P. (1992). Chronic lower airway disease in the dog and cat. *Probl. Vet. Med.*, **4**, 320-344.

Paramesh, H. (2002). Epidemiology of asthma in India. *Indian J. Pediatr.*, **69**, 309-312.

Park, S.J., Shin, W.H., Seo, J.W. and Kim, E.J. (2007). Anthocyanins inhibit airway inflammation and hypersensitivity in a murine asthma model. *Food and Chemical Toxicol.*, **45**, 1459-1467.

Rakesh, K.K., Cristha, H. and Paul, S.F. (2008) The “Classical” ovalbumin challenge model of asthma in mice. *Current Drug Targets*, **9**, 485-494.

Sofia, F.R., William, R.F., Kenneth, J.B. and Emma, J.K. (2008) Establishing the phenotype in novel acute and chronic murine models of allergic asthma. *Internal Immunopharmacol.*, **8**, 756-763.

Swirska, F.K., Sajic, D., Robbins, C.S., Gajewska, B.U., Jordana, M. and Stampfl, M.R. (2002). Chronic exposure to innocuous antigen in sensitized mice leads to suppressed airway eosinophilia that is reversed by granulocyte macrophage colony-stimulating factor. *J. Immunol.*, **169**, 3499-3506.

Tattersfield, A.E., Knox, A.J., Britton, J.R. and Hall, I.P. (2002). *Asthma Lancet.*, **360**, 1313-1322.

Temelkovski, J., Hogan, S.P., Shepherd, D.P., Foster, P.S. and Kumar, R.K. (1998). An improved murine model of asthma: selective airway inflammation, epithelial lesions and increased methacholine responsiveness following chronic exposure to aerosolized allergen. *Thorax, 53*, 848-856.

Torres, R., Picado, C. and Mora F. (2005). Use of the mouse to unravel allergic asthma: a review of the pathogenesis of allergic asthma in mouse models and its similarity to the condition in humans. *Arch. Bronconeumol.*, **41**, 141-152.

Toward, T.J., Smith, N. and Broadley, K.J. (2004). Effect of phosphodiesterase-5 inhibitor, sildenafil (Viagra), in animal models of airways disease. *Am. J. Respir. Crit. Care Med.*, **169**, 227-234.

Weiss, K.B. and Sullivan, S.D. (2001). The health economics of asthma and rhinitis. I. Assessing the economic impact of *J. Allergy Clin. Immunol.*, **107**, 3-8.

Yang, G., Li, L., Volk, A., Emmell, E., Petley, T., Giles-Komar, J., Rafferty, P., Lakshminarayanan, M., Griswold, D.E., Bugelski, P.J. and Das, A.M. (2005). Therapeutic dosing with anti-interleukin-13 monoclonal antibody inhibits asthma progression in mice. *J. Pharmacol. Exp. Ther.*, **313**, 8-15.

Yang, G., Volk, A., Petley, T., Emmell, E., Giles-Komar, J., Shang, X., Li, J., Das, A.M., Shealy, D., Griswold, D.E. et al. (2004). Anti-HL-13 monoclonal antibody inhibits airway hyperresponsiveness, inflammation and airway remodeling. *Cytokine*, **28**, 224-232.

Yoshida, M., Watson, R.M., Rerecich, T. and O'Byrne, P.M. (2005). Different profiles of T-cell IKN-gamma and IL-12 in allergen-induced early and dual responders with asthma. *J. Allergy Clin. Immunol.*, **115**, 1004-1009.

Yuk, J.E., Woo, J.S., Yun, C.Y., Lee, J.S., Kim, J.H., Song, G.Y., Uang, E.J., Hur, I.K. and Kim, I.S. (2007). Effects of lactose-ψ-sitosterol and ψ-sitosterol on ovalbumin-induced lung inflammation in actively sensitized mice. *Int. Immunol.*, **7**, 1517-1527.